Cynthia Levy

Professor of Medicine

University of Miami

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Cynthia Levy is a faculty member in the Department of Medicine at the University of Miami, USA. Her research primarily focuses on hepatology, with recent articles addressing topics such as primary biliary cholangitis and its treatment, chronic pruritus related to liver disease, and guidelines for managing hepatic porphyrias. Professor Levy's work contributes significantly to understanding liver diseases and improving therapeutic strategies for affected patients.

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Annika Bergquist

Karolinska University Hospital

SWEDEN

Cynthia Levy

Research Interests

Explore related searches

Contact this professor

About

Articles (27)

The effects of elafibranor in people with primary biliary cholangitis: a plain language summary

Primary biliary cholangitis: Personalizing second-line therapies

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers

Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry

Association of Liver Disease and Chronic Pruritus: A Case–Control Study

Featured Cover

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis

Acute hepatic porphyrias—A guide for hepatologists

Impact of implementation of national liver review board on liver allocation among patients with primary sclerosing cholangitis

Autoimmune hepatitis and pregnancy

Diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and x-linked protoporphyria: A patient-friendly summary of the 2023 evidence-based consensus guidelines

Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

New Treatment Paradigms in Primary Biliary Cholangitis

Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial

Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

Reply: Iron supplementation in protoporphyrias

Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis

Optimizing treatment of primary biliary cholangitis: Is good, good enough?

Impact on follow-up strategies in patients with primary sclerosing cholangitis

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis

Reply to: “Seladelpar in patients with primary biliary cholangitis: Need for a closer look!”

Primary Biliary Cholangitis

Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Collaborators (16)

Annika Bergquist

Christopher L. Bowlus

Michael Heneghan

Xavier Verhelst

Charles McWherter

Ewa Wunsch

Aparna Goel

Gideon M. Hirschfield

Karl Anderson

Andreas Kremer

Ewa Janczewska

Martti Färkkilä

PIETRO ANDREONE

Christoph Schramm

Aldo J. Montano-Loza

John Vierling

Make your next move.